文献速递医院感染防控细菌感染、耐药与抗菌药物

急性淋巴细胞白血病化疗后儿童疫苗免疫力衰减与接种应答:加拿大免疫研究网络研究

Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该多中心试验纳入化疗结束后4–12个月的急性淋巴细胞白血病(ALL)患儿74例及免疫正常对照78例,评估14种肺炎球菌血清型、百日咳毒素、破伤风类毒素和水痘的免疫力衰减,以及化疗后接种DTaP-IPV-Hib、PCV13和PPV23的免疫原性与安全性。结果显示患儿基线抗体水平低于对照,接种后抗体几何平均浓度显著升高并维持至12个月,无严重不良事件。

要点

  • ALL化疗后患儿对肺炎球菌、破伤风、百日咳和水痘的抗体水平低于健康对照。
  • 化疗后接种DTaP-IPV-Hib、PCV13和PPV23具免疫原性且耐受良好。
  • ALL患儿化疗后可从系统性再接种中获益。

核心结论

  • ALL化疗后儿童虽既往接种过疫苗,但对肺炎球菌血清型、破伤风、百日咳和水痘的抗体水平仍低于对照。
  • 化疗后接种DTaP-IPV-Hib、PCV13和PPV23具免疫原性且耐受良好。
  • ALL患儿化疗后可从系统性再接种中获益。

研究设计与样本

  • 多中心试验,纳入化疗结束后4–12个月的ALL患儿,排除婴儿ALL、复发ALL和干细胞移植受者。
  • 化疗后参与者74例,免疫正常对照78例。
  • 化疗后参与者同时接种DTaP-IPV-Hib和PCV13,2个月后接种PPV23,基线、接种后2个月和12个月测血清学,并通过调查捕获不良事件。

主要发现

  • 入组时化疗后参与者按年龄适龄接种DTaP的比例低于对照(41% vs 89%,P < .001)。
  • 入组时化疗后参与者按年龄适龄接种PCV的比例低于对照(59% vs 79%,P = .008)。
  • 调整既往疫苗剂次后,化疗后参与者对TT、PT、PCV血清型和水痘的几何平均浓度低于对照(P < .001)。
  • 接种后2个月,TT、PT和PCV血清型的几何平均浓度较基线升高(所有抗原P < .001),并维持至接种后12个月。
  • 接种后PPV23血清型抗体水平也升高(P < .001),未报告严重不良事件。

临床怎么用

  • 对完成化疗的ALL患儿应评估既往疫苗接种史并考虑系统性再接种。
  • 化疗后可接种DTaP-IPV-Hib、PCV13及后续PPV23,接种后抗体应答可维持至12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no uniform guideline for postchemotherapy vaccination of children with acute lymphoblastic leukemia (ALL). We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated children treated for ALL. METHODS: This was a multicenter trial of children with ALL enrolled 4-12 months postchemotherapy completion. Exclusion criteria included: infant ALL, relapsed ALL, and stem cell transplant recipients. Immunocompetent children were recruited as controls. Postchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later. Serology was measured at baseline, 2 and 12 months postvaccination. Adverse events were captured via surveys. RESULTS: At enrollment, postchemotherapy participants (n = 74) were less likely than controls (n = 78) to be age-appropriately immunized with DTaP (41% vs 89%, P < .001) and PCV (59% vs 79%, P = .008). Geometric mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy participants than controls after adjusting for previous vaccine doses (P < .001). Two months postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all antigens) and remained elevated at 12 months postvaccination. Antibody levels to PPV23 serotypes also increased postvaccination (P < .001). No serious adverse events were reported. CONCLUSIONS: Children treated for ALL had lower antibody levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination. Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated. Children with ALL would benefit from systematic revaccination postchemotherapy. CLINICAL TRIALS REGISTRATION: NCT02447718.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Top KA, Vaudry W, Morris SK, et al. Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study. Clin Infect Dis. 2020. PMID: 32067048. doi:10.1093/cid/ciaa163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。